



ACQUISITION OF RHENOFLEX

EXPANDING COATS' LEADING POSITION IN THE ATHLEISURE AND SPORTS FOOTWEAR MARKET

AUGUST 2022

TRANSACTION HIGHLIGHTS

Acquisition of Rhenoflex, a Leading Provider of Structural Footwear Components and Sustainable Reinforcement Solutions

Unique Opportunity for Coats to Further Expand its Footwear Platform
Through a Synergistic Combination with Texon

Consolidates Existing Presence in Highly Attractive and Fast-Growing
Athleisure and Sports Footwear Market

Highly Complementary Business to Texon and Coats with Expected Incremental Annual Recurring Cost Synergies of \$6m

Purchase Price of €115m (\$117m) Funded Through a 10% Equity

Placing

RHENOFLEX AT A GLANCE











COMPELLING STRATEGIC RATIONALE

1

Strengthens Position as Global Leader in Footwear Components


- Combines two global leaders in structural footwear components with enhanced scale, global reach and capability
- Consolidates Coats' presence in highly attractive and fast-growing athleisure and sports footwear market and positioning with key global brands
- Strengthens platform with combined sales from Rhenoflex, Texon and Coats' Footwear and Accessories business at c.\$425m on a last twelve-month basis to June-22



9

Highly Complementary
Addition to Texon and
Coats

- Complementary product offerings across footwear components and fashion accessories
- Strengthens credentials in sustainability and expands breadth of sustainable product innovations
- Enhanced capability through addition of Rhenoflex's in-house R&D team
- Attractive commercial opportunities to accelerate combined growth



1

Significant Value
Creation Potential with
Attractive Financial
Rationale

- Compelling cost synergy potential of combination with SG&A savings, procurement efficiencies and operational improvements expected to deliver annual cost savings of \$6m
- Attractive underlying revenue growth (expected FY22-26 CAGR of c.7%)
- Represents 9.3x LTM June-22 EBITDA and 6.2x on post-synergy LTM EBITDA basis
- Integration of businesses to be overseen by dedicated team

\$6m Annual synergies

7% FY 22-26 Revenue CAGR

COMBINATION ESTABLISHES GLOBAL LEADING FOOTWEAR PLATFORM

Consolidates Position in the Attractive Premium Athleisure and Sports Footwear Market














Footwear & **Accessories** ~\$425m

Combined LTM June-22 Revenue⁽¹⁾

HIGHLY COMPLEMENTARY TO TEXON AND COATS...



Complementary Product Offering Enhances Customer Proposition



Coats' Offerings



Threads



Engineered Yarns



Bags



Belts



End Markets and Applications



Customer Base



Sustainable Technologies

WITH FOCUS ON INNOVATION AND SUSTAINABILITY

Focus on Innovation and Technology

Pipeline of innovative new products



RhenoprintTM Multi-zone
Proprietary zero-waste
production technology



Vegan Product Line Complementary to existing eco-friendly products



Product DigitizationRFID / NFC chip integration



Leather Waste Recycling
New reinforcement product

Focus on Sustainability

Eco-friendly manufacturing inputs



Recycled Materials
Use of recycled plastics and leather



Renewable Materials
Use of decomposable, biological inputs

Sustainable production methods



Rhenoprint[™] Process Proprietary zero-waste production method



Circular Process
Closed loop production of sheets from factory waste

Industry technology leader with portfolio of innovative and sustainable offerings

SIGNIFICANT VALUE CREATION POTENTIAL

Highly Synergistic Combination Delivering Incremental Annual Cost Synergies of \$6m



Overview of Key Value Drivers

SG&A Savings

Procurement Efficiencies

Operational Improvements

Further Potential Upside from Revenue Synergies

Cost synergies are to be realised by the end of the first full year of ownership with a one-off integration cost of \$5m

ATTRACTIVE FINANCIAL RATIONALE



Attractive Outlook

FY22-26 Expected Revenue CAGR



+8%

Medium Term EBITDA Margin (Including Synergies)



KEY TRANSACTION TERMS

Attractive Financial Rationale



Purchase price of €115m (\$117m) EV

- Represents 9.3x LTM June-22 EBITDA and 6.2x LTM EBITDA on a post-synergy basis
- High Single Digit Revenue Growth (FY22-26 CAGR of c.7%)



Expected Annual Cost Synergies of \$6m

- To be achieved in the first full year of ownership
- \$5m one-off integration costs



 Acquisition of Rhenoflex standalone marginally dilutive, given equity placing

Overview of Transaction Structure



Consideration to be funded with 10% equity placing at announcement



Leverage to remain within 1-2x, prioritising strategic balance sheet flexibility



Transaction expected to close by the end of August



Integration to be overseen by dedicated team



Q&A will begin in 5 minutes

Participant joining details - Joining by Telephone:

United Kingdom 0800 640 6441 United Kingdom (Local) 020 3936 2999 All other locations +44 20 3936 2999

Access code: 035969

Press *1 to ask a question, *2 to withdraw your question, or *0 for operator assistance.

DISCLAIMER (1/3)

THIS PRESENTATION, ITS CONTENTS AND ANY INFORMATION PROVIDED AT THIS PRESENTATION ARE STRICTLY CONFIDENTIAL AND ARE FOR INFORMATION PURPOSES ONLY AND MUST NOT BE RELIED UPON FOR ANY PURPOSE. THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA (EXCEPT TO QIBS), CANADA (EXCEPT TO THOSE WHO ARE ACCREDITED INVESTORS AND PERMITTED CLIENTS), AUSTRALIA, JAPAN, SOUTH AFRICA, OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION OR PERSON WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESENTATION IS NOT AN OFFER OR INVITATION TO BUY OR SELL SECURITIES. IN REVIEWING THIS INFORMATION, YOU ARE ACKNOWLEDGING THE CONFIDENTIAL NATURE OF THIS INFORMATION AND ARE AGREEING TO ABIDE BY THE TERMS OF THIS DISCLAIMER.

This Presentation has been prepared by Coats Group plc (referred to herein as "Coats" or the "Company") solely for informational purposes. For the purposes of this notice, "the Presentation" shall mean and include the slides that precede this notice, this document, the oral presentation of the slides by the Company or any person on behalf of the Company, any audio-visual materials, its contents or any part of it, any question-and-answer session that follows the oral presentation, hard copies of this document and any materials distributed at, or in connection with the oral presentation. By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation. You must keep this Presentation confidential. This Presentation has been prepared and issued by and is the sole responsibility of the Company and is being furnished to each recipient solely for its own information and in connection with the preliminary discussions in relation to the Company.

This Presentation is strictly confidential and may contain material non-public information that is price-sensitive in nature ("Inside Information"). By receiving this document, you agree that you may be given Inside Information and that you may be considered an "insider", and may have legal or regulatory obligations which may extend to restrictions on your ability to (i) trade in the Company's securities (or related investments, such as derivatives, whose price or value depends on the price or value of the Company's securities), (ii) disclose the Inside Information to anyone else, (iii) use the Inside Information, or (iv) do anything whilst in possession of it that encourages someone else to deal in the relevant securities (or related investments). Any such disclosure, dealing or encouraging others to deal on the basis of such Inside Information, may amount to insider dealing under the Criminal Justice Act 1993 and market abuse under the Onshored Market Abuse Regulation (No. 596/2014) or other applicable laws and/or regulations in other jurisdictions. These restrictions will continue until the information contained herein that is Inside Information is made publicly available or is no longer material or price sensitive. Accordingly, this document may not be copied, distributed, published, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient to any other person (whether within or outside such person's organisation or firm), for any purpose or under any circumstances.

This Presentation is not a prospectus for the purposes of the Onshored Regulation (EU) 2017/1129 (as amended), Onshored Delegated Regulation (EU) 2019/980 and Onshored Delegated Regulation (EU) 2019/979 (together the "UK Prospectus Regulation"), Part VI of the Financial Services and Markets Act 2000 (the "FSMA") and the prospectus rules (as defined in section 73A(4) of the FSMA) of the Financial Conduct Authority (the "FCA") or otherwise and this Presentation has not been approved by the FCA or any other regulatory authority. This Presentation is not intended to provide, and must not be taken as, the basis of any decision by an investor to subscribe for or purchase any securities and should not be considered as a recommendation to acquire any securities of the Company. The Company has not decided whether or not to proceed with any offering of securities or proposed application for admission of its securities to trading on a regulated market in the United Kingdom. The recipient must make its own independent assessment and such investigations as it deems necessary and is advised to conduct its own due diligence with respect to the Company

The information contained in this Presentation is strictly private and confidential and may not be reproduced, redistributed or disclosed in any way in whole or in part to any other person without the prior written consent of the Company. Save as set out below, this Presentation has been prepared on the basis of information held by the Company and also from publicly available information. This Presentation does not purport to contain all the information that may be required by the recipient to make an evaluation of the Company. The Company prepared this Presentation on the basis of information which it has and from sources believed to be reliable. To the extent available, the industry, market and competitive position data contained in this Presentation come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, they that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are by reference to the time this Presentation was prepared and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. None of the Company, Citigroup Global Markets Limited ("Citi"),

DISCLAIMER (2/3)

None of Citi or Peel Hunt or any of their respective directors, officers, employees, agents, affiliates and consultants ("Associates") or advisors have independently verified the information in this document and such information does not constitute a recommendation from either Citi or Peel Hunt to you. None of Citi, Peel Hunt or their Associates accepts any responsibility, obligation or liability whatsoever for, or makes any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of, the information in this Presentation or whether any information has been omitted from the Presentation or as to any other information relating to the Company, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation, its contents or otherwise arising in connection therewith. Each of Citi, Peel Hunt and their Associates disclaims, to the maximum extent permitted by applicable law and regulation, all and any indirect or direct responsibility and liability whether express or implied, arising in tort, contract or otherwise, which they might otherwise have in respect of (i) this Presentation or any information contained therein and (ii) any errors, omissions or misstatements contained in this Presentation. This Presentation has not been independently verified. None of Citi, Peel Hunt or their Associates shall have any liability whatsoever (in negligence or otherwise) for any direct, indirect or consequential loss, damages, costs or prejudices arising from the use of this Presentation or otherwise arising in connection with this Presentation. No duty of care is owed or will be deemed to be owed to you or any other person by Citi, Peel Hunt or their Associates in respect of the Presentation.

No representation or warranty, express or implied, is given by or on behalf of the Company or any of its parent or subsidiary undertakings or any of such person's respective directors, officers, employees, agents, affiliates or advisors as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of the information or opinions contained in this Presentation or otherwise made available nor as to the reasonableness of any information contained herein or therein and no responsibility or liability (including in respect of direct, indirect or consequential loss or damage) is assumed by any such persons for such information or opinions or for any errors or omissions. The recipient acknowledges that neither it nor the Company intends that the Company act or be responsible as a fiduciary to the recipient of this document or presentation, its management, stockholders, creditors or any other person. Each of the recipient and the Company by accepting and providing this Presentation respectively expressly disclaims any fiduciary relationship and agrees that the recipient is responsible for making its own independent judgments with respect to any transaction and any other matters regarding this Presentation.

The recipient should conduct its own independent investigation and assessment as to the validity of the information contained in this Presentation, and the economic, financial, regulatory, legal, taxation, stamp duty and accounting implications of that information. The recipient confirms that it is not relying on any recommendation or statement of the Company, Citi, Peel Hunt or any of their Associates. The recipient is strongly advised to consult its own independent advisors on any economic, financial, regulatory, legal, taxation, stamp duty and accounting issues relating to the information contained in this Presentation.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections and opinions ("Forward Statements"), which are based on current assumptions and estimates by the management of Coats. These Forward Statements include all matters that are not historical facts. These Forward Statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. By their nature, Forward Statements involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Company. Past performance cannot be relied upon as a guide to future performance and should not be taken as a representation that trends or activities underlying past performance will continue in the future. No representation or guarantee is made or will be made that any Forward Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward Statements. Similarly, no representation or guarantee is given that the assumptions disclosed in this Presentation upon which Forward Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. Each of the Company, Citi, Peel Hunt, and their respective Associates undertakes no obligation to update these Forward Statements, which speak only as at the date of this Presentation, and have not been audited or otherwise independently verified, and will not publicly release any revisions that may be made to these Forward Statements, which may result from events or circumstances arising after the date of this Presentation. No statement in this Presentation is intended to be a profit forecast. As a resul

Citi is authorised by the Prudential Regulation Authority (the "PRA") and regulated in the United Kingdom by the FCA and the PRA. Citi is registered with registered number 01763297 and has its registered office at 33 Canada Square, Canary Wharf, London E14 5LB, United Kingdom. Peel Hunt is authorised and regulated in the United Kingdom by the FCA. Peel Hunt is registered number OC357088 and has its registered office at 7th Floor, 100 Liverpool Street, London EC2M 2AT, United Kingdom. Each of Citi and Peel Hunt is acting exclusively for the Company and no one else in connection with this Presentation or any future transaction in connection with it. Each of Citi and Peel Hunt will not regard any other person (whether or not a recipient of this Presentation) as a client and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for the giving of advice in relation to any transaction, matter or arrangement of securities of the Company referred to in this Presentation.

DISCLAIMER (3/3)

This Presentation is not an offer to sell or a solicitation of an offer to buy any securities and is not for publication or distribution in the United States except to QIBs (as defined below). The securities have not been, and will not be, registered under the U.S. Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and in accordance with any applicable securities law of any state or other jurisdiction of the United States. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of any securities in the United States. This Presentation may not be viewed by persons within the United States (within the meaning of Regulation S under the Securities Act) other than "qualified institutional buyers" ("QIBs") (as defined in Rule 144A under the Securities Act) and in accordance with any applicable securities law of any state or other jurisdiction of the United States.

This Presentation is not, and under no circumstances is it to be construed as, an advertisement or a public offering of securities of the Company in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way expressed an opinion about the securities described in the Presentation and any representation to the contrary is an offence.

The distribution of securities of the Company in Canada is to be made only in the provinces of Alberta, British Columbia, Ontario and Québec and on a private placement basis only exempt from the requirement that the Company prepare and file a prospectus with the relevant Canadian securities regulatory authorities and only to those who are both "accredited investors" within the meaning of National Instrument 45-106 – Prospectus Exemptions (or section 73.3(1) of the Securities Act (Ontario), as applicable) (each, an "Accredited Investor") and "permitted clients" within the meaning of National Instrument 31-103 – Registration Requirements, Exemptions and Ongoing Registrant Obligations (each, a "Permitted Client"). The Company is not a "reporting issuer", as such term is defined under applicable Canadian securities legislation, in any province or territory of Canada, its securities are not listed on any stock exchange in Canada and there is currently no public market for the securities in Canada. The Company currently does not intend to file a prospectus or similar document with any securities regulatory authority in Canada qualifying the resale of its securities to the public in any province or territory of Canada or listing its securities on any stock exchange in Canada. Therefore, there will be no public market in Canada for the securities and the resale or transfer of the securities will be subject to restrictions. Accordingly, any resale of securities of the Company must be made in accordance with applicable securities laws, and which may require resales to be made in accordance with exemptions from registration and prospectus requirements. Canadian purchasers are advised to seek legal advice prior to any contemplated purchase and resale of securities of the Company.

Save as set out above, this Presentation is only addressed to and directed at persons (i) in member states of the European Economic Area ("EEA") who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation EU) 2017/1129), as amended ("Qualified Investors") and (ii), in the United Kingdom, who are "qualified investors" as defined in Regulation 2(e) of the UK Prospectus Regulation, who (i) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) are other persons to whom this Presentation may otherwise lawfully be communicated (all such persons referred to in (i), (ii) and (iii) together being referred to as "Relevant Persons"). The Presentation must not be acted or relied on (i) in the United Kingdom, by persons who are not Relevant Persons and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Save as set out above, any investment activity to which the Presentation relates is available only (i) in the United Kingdom, to Relevant Persons and (ii) in any member state of the EEA, to Qualified Investors, and may be engaged in only with such persons. This Presentation does not constitute an offer or invitation for the sale or purchase of securities or any businesses or assets described in it, nor does it purport to give legal, tax or financial advice. Nothing in the Presentation and you are not a Relevant Person or a Qualified Investor you must return it immediately to the Company and not copy, reproduce or otherwise disclose it (in whole or in part).

Information in this Presentation has not been prepared with regard to matters that may be of particular concern to Canadian purchasers and accordingly, should be read with this in mind. The securities of the Company are not denominated in Canadian dollars. The value of the securities of the Company to a Canadian purchaser will fluctuate with changes in the exchange rate between the Canadian dollar and the currency of the securities.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this Presentation (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts ("NI 33-105"), the Global Coordinator is not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

The Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to or acquire, securities of the Company, or an inducement to enter into investment activity in any country, and is not directed at persons in jurisdictions including the United States, Canada, Australia, Japan, South Africa, or in any other jurisdiction in which such offer, solicitation, inducement or sale would be unlawful prior to registration, unless an exemption under the relevant securities laws of such jurisdiction is applicable. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

The Presentation is not for publication, release or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken, transmitted or distributed, directly or indirectly into such jurisdiction. Any failure to comply with the foregoing restrictions may constitute a violation of United States or other national securities laws. You are required to inform yourself of, and comply with, all such restrictions and prohibitions and none of the Company, the Global Coordinator, its Associates nor any other person accepts liability to any person in relation thereto. This Presentation, and any matter or dispute (whether contractual) arising out of it, shall be governed and construed in accordance with English law and the English courts shall have exclusive jurisdiction in relation to any such matter or dispute.